Amsterdam, August 27th 2018 – The Dutch healthtech company Nico.lab prepares for an IPO in Australia after the company has previously collected 3 million euros from Australian investors. In addition, Nico.lab will enter the US market. Nico.lab is the result of a collaboration between Amsterdam UMC and health tech venture builder NLC. With years of intensive clinical research in the Amsterdam UMC, the company has developed StrokeViewer®, a software product that significantly speeds up the diagnosis and treatment of strokes. Nico.lab now focuses on making StrokeViewer based on artificial intelligence (AI) available to more and more patients.
In the treatment of stroke, speed is crucial to limit the brain damage for the patient as much as possible; a patient quickly loses 27 healthy days of life per minute of treatment delay. Using AI, Nico.lab software analyzes brain scans to recognize and accurately assess stroke indicators. This all happens in a few minutes and thus considerably increases the chance of a positive result for the patient. In addition, the algorithm contains self-learning ability, and provides additional knowledge about this common disease and the functioning of the brain in such a serious situation.
This year, StrokeViewer is tested among 3,000 patients in various hospitals in the Netherlands and compared with the current method that has been used for years to diagnose a stroke. In other countries, the results achieved with StrokeViewer did not go unnoticed and Nico.lab recently won a European prize of half a million euros. The company has also been asked to participate in clinical trials in North America and Australia.
In order to meet the growing demands for StrokeViewer, new investments are necessary. The large Australian investment interest has resulted in Nico.lab attracting 3 million euros in investments from various investors. The investment round is part of an IPO in Australia. The IPO of Nico.lab is planned for early 2019. In addition to interest from Australia, there has also been interest from North America. Tech giants, including Google, Intel and HP have entered into a partnership with Nico.lab to prepare for the introduction of StrokeViewer on the US market in early 2019.
Merel Boers, Chief Research Officer at Nico.lab: “We are very pleased with the great interest in our product that combines the latest clinical research results with state-of-the-art AI technology. This movement shows that an impact can be made in health care. We want to work hard on further expanding StrokeViewer in the coming years to help more patients. ”
Nico.lab’s StrokeViewer uses Artificial Intelligence to shorten the time of determining the appropriate treatment for strokes to a few minutes, where it can sometimes take hours under the current method. StrokeViewer is now being rolled out in several Dutch hospitals. Nico.lab is the result of a collaboration between Amsterdam UMC and health tech venture builder NLC.
For more information please contact:
020 244 0852 / email@example.com